Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. cut its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 24.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 129,164 shares of the biopharmaceutical company’s stock after selling 41,844 shares during the quarter. Federated Hermes Inc. owned 0.11% of Catalyst Pharmaceuticals worth $2,171,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System lifted its stake in Catalyst Pharmaceuticals by 4.7% during the third quarter. State Board of Administration of Florida Retirement System now owns 28,660 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 1,290 shares during the last quarter. Teacher Retirement System of Texas increased its position in Catalyst Pharmaceuticals by 5.3% in the third quarter. Teacher Retirement System of Texas now owns 28,682 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 1,456 shares during the period. Cerity Partners LLC increased its position in Catalyst Pharmaceuticals by 11.5% in the fourth quarter. Cerity Partners LLC now owns 17,231 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 1,780 shares during the period. Raymond James & Associates increased its position in Catalyst Pharmaceuticals by 4.2% in the fourth quarter. Raymond James & Associates now owns 50,279 shares of the biopharmaceutical company’s stock worth $845,000 after buying an additional 2,045 shares during the period. Finally, CenterBook Partners LP increased its position in Catalyst Pharmaceuticals by 20.0% in the third quarter. CenterBook Partners LP now owns 13,577 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 2,259 shares during the period. 79.22% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 25,000 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $15.68, for a total transaction of $392,000.00. Following the completion of the sale, the director now directly owns 348,874 shares in the company, valued at approximately $5,470,344.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 12.10% of the company’s stock.

Analyst Upgrades and Downgrades

CPRX has been the topic of several analyst reports. StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $34.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. TheStreet raised Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. Finally, HC Wainwright reissued a “buy” rating and set a $24.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, March 1st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $26.43.

Catalyst Pharmaceuticals Stock Up 1.4 %

NASDAQ:CPRX opened at $14.89 on Monday. The business’s 50-day moving average price is $15.54 and its 200 day moving average price is $14.64. The firm has a market cap of $1.76 billion, a P/E ratio of 24.41, a PEG ratio of 0.82 and a beta of 0.89. Catalyst Pharmaceuticals, Inc. has a 52-week low of $11.09 and a 52-week high of $17.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.04. The firm had revenue of $110.57 million for the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. Sell-side analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.